Strategies for Overcoming <em>KRAS</em> Mutations in Lung Cancer

David Gandara, MD, professor, Division of Hematology/Oncology, University of California Davis Comprehensive Cancer Center, discusses overcoming KRAS mutations in lung cancer.

Clinical Pearls

David Gandara, MD, professor, Division of Hematology/Oncology, University of California Davis Comprehensive Cancer Center, discusses overcomingKRASmutations in lung cancer. Gandara presented on this topic at the15th Annual International Lung Cancer Congress&reg;.

  • KRASmutations tend to predict less response to chemotherapy or TKIs.
  • It has been extremely difficult to develop drugs that directly inhibit KRAS.
  • MEK inhibitors in combination with chemotherapy have shown downstream activity.
  • SWOG 1408 will test this hypothesis with a MEK inhibitor (trametinib) in combination with chemotherapy (docetaxel) or an AKT inhibitor (GSK795).